These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38493408)

  • 1. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
    Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
    Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.
    Cao L; Liu M; Ma X; Rong P; Zhang J; Wang W
    Curr Med Chem; 2024; 31(17):2414-2430. PubMed ID: 37936457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
    Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
    Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel matrix metalloproteinases-related prognostic signature in hepatocellular carcinoma.
    Yuan X; Yang L; Gao J; Mao X; Zhang Y; Yuan W
    Aging (Albany NY); 2024 May; 16(10):8667-8686. PubMed ID: 38761174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.
    Xu JH; Guan YJ; Qiu ZD; Zhang X; Zi LL; Zhou Y; Chen C; Yu J; Zhang YC; Wang WX
    Oxid Med Cell Longev; 2021; 2021():6485871. PubMed ID: 34795841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
    Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
    Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHLDA2 reshapes the immune microenvironment and induces drug resistance in hepatocellular carcinoma.
    Feng K; Peng H; Lv Q; Zhang Y
    Oncol Res; 2024; 32(6):1063-1078. PubMed ID: 38827322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
    Xu Q; Wang Y; Huang W
    Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.